Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
Waldenstrom macroglobulinemia (WM) is a type of incurable, indolent B-cell lymphoma that is prone to relapse. Over time, treatment strategies have progressed from cytotoxic drugs to rituximab (R)- or bortezomib (V)-based regimens, and have now entered into an era of Bruton tyrosine kinase inhibitor...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2024-01-01
|
| Series: | Blood Science |
| Online Access: | http://journals.lww.com/10.1097/BS9.0000000000000179 |